Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 1, Pages 68
Publisher
MDPI AG
Online
2019-12-20
DOI
10.3390/ijms21010068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma
- (2019) Sarah E Josefsson et al. Cancer Immunology Research
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia
- (2019) Satyen H. Gohil et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells
- (2019) Ahmet Eken et al. JOURNAL OF CLINICAL IMMUNOLOGY
- The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
- (2019) Jun-Xia Cao et al. CYTOTHERAPY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
- (2019) Simo Xia et al. Cellular & Molecular Immunology
- The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2019) Yi‐Xin Zou et al. HEMATOLOGICAL ONCOLOGY
- A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
- (2018) Hannah R. Robinson et al. BLOOD
- Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
- (2018) Gonzalo Blanco et al. OncoImmunology
- Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
- (2018) Georg Aue et al. JOURNAL OF IMMUNOLOGY
- Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
- (2018) Bola S. Hanna et al. LEUKEMIA
- Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
- (2018) Jan A. Burger et al. BLOOD
- Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia
- (2017) Saeid Taghiloo et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
- (2017) K Kondo et al. LEUKEMIA
- Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
- (2017) Monika Podhorecka et al. Oncotarget
- Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
- (2016) C. E. Ryan et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
- (2016) Viralkumar Patel et al. CLINICAL CANCER RESEARCH
- T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
- (2016) Marzia Palma et al. HAEMATOLOGICA
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
- (2016) A Vardi et al. LEUKEMIA
- Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
- (2016) Jun Chen et al. MOLECULAR CANCER THERAPEUTICS
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
- (2016) Marzia Palma et al. HAEMATOLOGICA
- Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
- (2015) D. Masso-Valles et al. CANCER RESEARCH
- Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
- (2015) A. Vardi et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias
- (2015) Deepesh P. Lad et al. LEUKEMIA & LYMPHOMA
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival
- (2015) Z -Z Yang et al. Blood Cancer Journal
- The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
- (2015) A. Wiestner HAEMATOLOGICA
- How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
- (2014) A. P. Kater et al. BLOOD
- Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
- (2014) Julio Gomez-Rodriguez et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2014) Wen Gao et al. JNCI-Journal of the National Cancer Institute
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
- (2013) R. Wong et al. HAEMATOLOGICA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma
- (2013) Zhi-Zhang Yang et al. PLoS One
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
- (2012) J. C. Riches et al. BLOOD
- Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
- (2012) A. G. Ramsay et al. BLOOD
- Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia
- (2012) Chava Perry et al. LEUKEMIA & LYMPHOMA
- Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
- (2012) Farhad Jadidi-Niaragh et al. TUMOR BIOLOGY
- A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
- (2011) D. Bagnara et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
- (2011) C. Nunes et al. CLINICAL CANCER RESEARCH
- CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia
- (2011) Dianne Pulte et al. Clinical Lymphoma Myeloma & Leukemia
- Origins of CD4+ effector and central memory T cells
- (2011) Marion Pepper et al. NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis
- (2009) J. M. Fletcher et al. JOURNAL OF IMMUNOLOGY
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
- (2008) Alan G. Ramsay et al. JOURNAL OF CLINICAL INVESTIGATION
- Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people
- (2008) Sven Koch et al. Immunity & Ageing
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started